InstructorRoyed Training
TypeOnline Course
Student Enrolled2
(1 ratings)
Price$930 / 65100 INR.
Buy NowBook Now
Loading
Loading
Drug Regulatory Affairs and Pharmacovigilance dual specialization by royed training

Introduction

Who should attend

Learning Outcome

Features

Related Courses

About RA

regulatory affairs pharmacovigilance course

This comprehensive one-year dual-specialisation programme provides in-depth expertise in both Drug Regulatory Affairs and Pharmacovigilance, two of the most essential pillars of the life-sciences industry. Designed to match the latest global trends, the updated curriculum now includes advanced modules on Artificial Intelligence (AI) in Regulatory Affairs, Real-World Evidence (RWE), Real-World Data (RWD) and Healthcare Database Management. As a result, learners gain a future-ready regulatory and drug-safety skillset aligned with the rapidly evolving pharmaceutical landscape.

The programme combines regulatory, compliance and drug-safety domains into a single structured learning path. Therefore, learners gain complete understanding of drug regulation, registration, marketing authorisation submissions, safety reporting and post-marketing surveillance. Upon completion, participants are awarded two separate certifications — one in Drug Regulatory Affairs and another in Pharmacovigilance — significantly enhancing their professional competency.

Why This Dual Specialization?

This PG Certification is carefully designed to develop industry-ready Regulatory Affairs and Pharmacovigilance Managers. Through practical, real-life job simulations, participants learn how regulatory and PV departments work in actual pharmaceutical settings. Consequently, the course is ideal for professionals who want to build strong expertise in both domains while advancing their career prospects across pharma, biotech, CROs and regulatory consulting.

Course Snapshot

  • Course Code: RYD-101
  • Title of the course: PG Certification in Drug Regulatory Affairs and Pharmacovigilance (PGDRAPV)
  • Nature of the course : Online distance learning course. So, course can be accessed online across anywhere 24×7.
  • Course duration : 1 Year.
  • Certification : Certificate will be provided at the end of the successful completion of the course. Two separate certificates will be issued. One on drug regulatory affairs and other on pharmacovigilance.
  • Eligibility: Graduation in any discipline. Moreover, Third and final year students can also pursue the course.

A Future-Ready Training Experience

With its combination of regulatory, safety, AI and real-world data competencies, this dual specialisation empowers learners to confidently handle end-to-end regulatory and PV responsibilities. By the end of the course, participants are prepared for a wide range of roles in Regulatory Affairs, Pharmacovigilance, Drug Safety, Compliance, Clinical Research Support and Regulatory Operations.

Who should attend this course? 

  • Professionals working in Regulatory Affairs, Pharmacovigilance, Drug Safety, Compliance, Clinical Ops, Quality Assurance who want to deepen their knowledge across both domains.
  • Life-sciences graduates (Pharmacy, Biotechnology, Life Science, Chemistry) or those aspiring to enter the regulatory or PV function.
  • Individuals wishing to upgrade their skills to include emerging areas like AI, RWD/RWE and healthcare-data management in the pharma/biopharma domain.
  • Corporate teams in pharma/biopharma who want cross-functional capability in regulatory strategy + safety + data-driven decision-making.

Learning Outcome

By the end of the programme you will be able to:

  • Understand the full lifecycle of drug development —from discovery through to post-market safety monitoring.
  • Apply global regulatory frameworks (US, EU, India, MENA, ASEAN) and handle dossier preparation/submission/variation.
  • Design and implement pharmacovigilance systems: case processing, signal detection, aggregate reporting, risk management.
  • Leverage RWD to generate RWE and apply it in regulatory submissions, safety assessments and lifecycle strategy.
  • Use AI tools and techniques in regulatory affairs and pharmacovigilance workflows — e.g., document automation, predictive analytics, database mining.
  • Manage and analyse healthcare and safety databases, integrate RWD sources, ensure data quality and governance.
  • Simulate real-job scenarios in regulatory affairs & pharmacovigilance to improve decision-making and strategic planning.
  • Combines two highly sought-after fields — Regulatory Affairs + Pharmacovigilance — into one programme, giving you versatility and enhanced employability. 
  • The updated focus on AI, RWD/RWE and healthcare database analytics brings you into the frontier of the industry where regulatory and safety decisions are increasingly data-driven.
  • Real-life simulations and case studies prepare you not just theoretically but practically for job roles across pharma/biopharma.
  • Online self-paced format allows flexibility for working professionals.

Career in Drug Regulatory Affairs

A career in Regulatory Affairs is very challenging, but highly rewarding. It opens up lot of opportunities for professionals. But the regulatory job covers a variety of disciplines. Regulatory professional involved involved in regulatory submission, compliance, clinical trials, quality assurance, drug safety, pharmacovigilance.

The Pharma and biopharma industry is growing at a rapid pace, but there is a rising concern over the safety and efficacy. Hence, the major objective of the regulatory department to maintain safety and efficacy of the drugs and biopharmaceutical molecules. In fact, to maintain safety and efficacy in pharmaceutical and biopharmaceutical products, regulatory agencies like US FDA, EMA, MHRA UK, DCGI, TGA – Australia, NMPA – China etc. all over the world are imposing number of regulation. Therefore, these regulations are evolving and changing every other day. Most importantly, regulatory professionals must have thorough knowledge about the updated regulations. Certainly, sound regulatory knowledge helps them to take strategic decision effectively. Hence, this has resulted in creation of regulatory department with certified regulatory affairs professionals. Therefore, it help companies to meet these requirements with ease.

About regulatory affairs job>> Learn here

Career in Pharmacovigilance

Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem. Pharmacovigilance deals with 4 important aspects. Adverse Event Case Management including expedited reporting, Aggregate Reporting, Signal Intelligence; and Risk Management. A professionals should have excellent understanding on these aspects. The aims of pharmacovigilance within the industry are essentially the same as those of regulatory agencies; that is to protect patients from unnecessary harm by identifying previously unrecognised drug hazards, elucidating pre-disposing factors, refuting false safety signals and quantifying risk in relation to benefit. Although the perspectives of companies and the regulatory agencies may be different they now work more and more closely together and share information. However, central pharmacovigilance units in major pharmaceutical companies in many instances are far better resourced and have much greater ‘in-house’ expertise on the safety of their particular products.

What is the advantage of ours Regulatory Affairs and Pharmacovigilane dual course?

Royed Training’s dual specialization course in Drug Regulatory Affairs and Pharmacovigilance provides a comprehensive education that prepares students for critical roles in the pharmaceutical industry. Therefore, by integrating these two essential areas into a single program, students gain a robust understanding of both the regulatory requirements necessary for bringing drugs to market and the ongoing safety monitoring required post-approval. Moreover, this dual focus equips graduates with the skills to navigate complex regulatory landscapes, ensure compliance, and maintain high safety standards, making them highly valuable to employers. Additionally, the course’s broad scope enhances career versatility, allowing graduates to pursue diverse opportunities within the fields of regulatory affairs and pharmacovigilance.

Section 1Fundamental of Drug Discovery and Development | US Regulatory Affairs
Lecture 1Introduction to R&D Process & drug discovery
Lecture 2Investigational New Drug Application
Lecture 3New Drug Application (NDA)
Lecture 4Basic concept and understanding of the Generic Drug
Lecture 5Abbreviated New Drug Application (ANDA)
Lecture 6Regulatory Requirements for Non-clinical Studies | Types of Non-clinical studies 
Lecture 7Types and Timing of Non-clinical Studies 
Lecture 8USFDA Expedited Programs (Detailed Understanding)
Lecture 9505(j) ANDA, 505(b)(2) NDA, 505(b)(1) NDA
Lecture 10Concept of Authorized Generics: Key Understanding
Lecture 11Concept of Exploratory IND
Lecture 12Patent & Exclusivity - Strategic Understanding | Patent Restoration| Orphan Drug Exclusivity (ODE) | NCE & NCI Exclusivity | GAIN Exclusivity | Pediatric Exclusivity | 180 days exclusivity
Lecture 13Orphan Drug Designation
Lecture 14Advance Learning on 505B2 Pathway
Lecture 15Chemistry, Manufacturing & Controls - Fundamental Understanding
Lecture 16Review on Drug Discovery and Development 
Lecture 17Complete Response Letter | Key understanding | Management and Action Plan
Lecture 18Handling of orange book
Lecture 19Review on Drug Discovery and Development 
Lecture 20Understanding on Clinical Trials  and Clinical Research 
Lecture 21Clinical Trial Protocol Writing
Lecture 22Ethics in Clinical Research
Lecture 23Informed Consent | Practical Training on preparing ICF | Ready Templates
Lecture 24FDA Forms and How to fill the resources
Lecture 25Strategic Discussion: PreIND, EOP1, EOP2 - What to expect !
Lecture 26Preformulation Study in Drug Development 
Lecture 27Regulatory Requirements for Preformulation Study 
Lecture 28Logical Sequence of Preformulation Study | Case Insights | Strategies for preformulation studies  
Lecture 29Introduction to ICH | Members | Guidelines 
Lecture 30ICH Q1 : Stability Guideline | Matrixing | Bracketing
Lecture 31ICH Q2 : Analytical Validation 
Lecture 32ICH Q3 : Impurities
Lecture 33Rest of ICH Q Family Guidelines
Lecture 34Emergency Use Authorization (EUA) | EUA Pathways | Criteria | Justification | Early Discussion with FDA | LOA | Factsheets 
Lecture 35Fundamental of CMC | Detailed understanding of CMC section writing | Important Points regarding CMC | Drug Product and Drug Substance | Excipient, FP, Analysis and Stability Study Requirements
Section 2European Drug Regulatory Affairs
Lecture 36Orientation to European Countries and National Regulatory Bodies
Lecture 37EU Drug Discovery Development to Commercialization (Step By Step)
Lecture 38Overview of EU Regulation 
Lecture 39EMA and EMA Authorisation Process
Lecture 40EU MA Application Types and Strategic Planning
Lecture 41EU MA Procedure - Centralised, Decentralised, Mutual Recognition, National Procedure 
Lecture 42EU MA Strategic Planning: Full, Full-mixed, hybrid applications. Generic, Similar biologic application pathway, Well-established use application, Fixed combination application, Informed consent application
Lecture 43Validity of the EU MA  - Renewal steps, Cessation of the marketing authorisation, Significance of "Placed in Union Market", Suspension or withdrawal & EU MA for licensed products
Lecture 44Data Exclusivity and Market Protection - Supplementary Patent Protection, Exclusivity, 6/10 Rule, 8+2+1 Formulae
Lecture 45EU Orphan Medicinal Products Regulation
Lecture 46EU variation -Types, Requirement & Planning - IA, IAIN, IB, II ; US FDA Variation AR, CBE-0, CBE-30, PAS - Strategic Discussion | Similarities & Differentiation
Lecture 47Conditional marketing authorisation | Marketing authorisation under exceptional circumstances
Lecture 48Summary of Product Characteristics 
Lecture 49Compassionate Use
Lecture 50IMPD | Significance | Format of IMPD | Differences with CTA, IB, IND
Lecture 51Investigator’s Brochure | Significance | Format of IB | Preparing different sections of IB
Lecture 52Paediatric use marketing authorisation (PUMA) & Paediatric Investigation Plan (PIP)
Lecture 53EU Prime Designation 
Lecture 54Accelerated assessment by EMEA
Lecture 55EU Adaptive Pathway
Lecture 56European public assessment report (EPAR) - Importance, Component, Management, Updation 
Lecture 57SPOR  - Concept of Master Data Management  
Lecture 58MHRA - UK Regulation 
Lecture 59The 'sunset clause' for marketing authorisation of pharmaceuticals
Section 3 Regulatory Strategic Management and planning
Lecture 60Regulatory Strategies in different phases of Clinical Trial
Lecture 61Advance study on Para IV Filing
Lecture 62Para IV Notice
Lecture 63Evergreening - Patent Life Extension Strategies
Lecture 64Pay For Delay Strategy
Lecture 65REMS Strategic Planning
Lecture 66Compulsory Licensing
Lecture 67Licensing & Technology Transfer
Lecture 68In-Licensing Vs. Outlicensing
Lecture 69LOE Strategies for Innovator Brands with case study
Lecture 70Paediatric Exclusivity and Paediatric Study Plan Development
Lecture 71Drug Re-purposing
Lecture 72Practical Queries on different USFDA application and Filing
Lecture 73Publication Management from Regulatory perspective
Lecture 74Juxtapid Case Study
Lecture 75New Indication Approval Process and Promotion
Lecture 76OTC Switch
Section 4Good Manufacturing Practices
Lecture 77Certification Pharmaceutical Companies / Plants
Lecture 78Premises & Plant Layout Designing
Lecture 79Sanitation and Hygiene
Lecture 80Equipment
Lecture 81Production Modules
Lecture 82GMP Documentation
Lecture 83Quality Control
Lecture 84Handling of Product Complaint
Lecture 85GMP Storage
Lecture 86ISO and ISO Audits
Lecture 87Pharmaceutical SOPs
Lecture 88SOP Automation
Section 5 Submission Dossier : CTD | ACTD | DMF - SMF-ANDA | 505(b)(2) | NCE | Petittion| Prior Approval Submission
Lecture 89Advance Practical Training on Dossier Preparation focusing on drug registration in export countries
Lecture 90CMC Dossier & Compliance Management
Lecture 91Electronic Common Technical Document (ECTD)
Lecture 92Advance Practical Training on Dossier Preparation focusing on drug registration in export countries 
Lecture 93Key Consideration for Drug Master File Preparation and Submission 
Lecture 94Practical Understanding on Drug Master File Preparation and Submission
Lecture 95Site Master File - Detailed Understanding 
Lecture 96DMF Completeness Assessment
Lecture 97Drug Master File - Fees
Lecture 98Drug Master File - Global Perspective [Across Different Regions]
Lecture 99Importance of effective dossier management
Lecture 100Common deficiencies in CTD submission dossier
Lecture 101Certificate of Analysis
Lecture 102Detailed Understanding on ANDA Fees
Lecture 103Prior Approval Submission 
Lecture 104Detailed Understanding on ANDA Fees
Lecture 105Detailed Understanding on 505(b)(2) VS. Suitability Petition : Case Based Learning
Lecture 106NCE Vs. 505b2 application - Case Based Learning 
Lecture 107FTF - 180 Days Exclusivity - Case Based Learning
Lecture 108Classic case study of the 505b2 filing : Case Based Learning
Lecture 109Strategic Planning in Combating 30 months stay strategies of innovator company- Case Based Learning
Lecture 110Discussion on 85 common deficiency in CTD submission dossier
Lecture 111Asean Common Technical Document (ACTD) 
Section 6Quality issues, Warning Letter, CAPA and Data Integrity
Lecture 112Data Integrity issues in Pharmaceutical Industry
Lecture 113Establishment Inspection Report | 483 Observations | USFDA Warning Letter | Handling of FDA inspection | Closing of Warning Letter 
Lecture 114Electronic Batch Record for effective compliance management | Key Understanding | Functionalities | Importance in managing data integrity
Lecture 115RTQs | Response to Queries | How to handle Regulatory Queries  
Section 7Bioequivalence Study
Lecture 116PKPD in Drug Discovery | PK-PD trial | Understanding PKPD from regulatory perspective in drug approval process
Lecture 117Bioequivalence Study | Study design | Different types of BE Studies
Lecture 118Bioequivalence Study | Study design | Parallel Study | Crossover study design | Other alternative study designs | Blood Sampling Planning  | Analyte | Bioanalytical Methods Validation  | Statistical Model  | Ln Transformation  | Dose normalisation | Confidence interval acceptance criteria
Lecture 119Biopharmaceutical Classification System (BCS) | Types | Biowaivers | BCS tool for drug development and regulatory submission 
Lecture 120Bioequivalence Study - Discussion - Timeline of stability study and bioequivalence study 
Lecture 121Bioequivalence Study - Discussion - Dissolution Testing
Lecture 122Bioequivalence Study - Generic Approval and Additives Labeling Requirements 
Section 8Variation Management
Lecture 123Introduction to Variation Management | Reasons for Variation | Working in Variation Department 
Lecture 124Variation Classification | Basis of Classification | US and EU Variation Classification | Other region variation guideline.
Section 9Stability Study
Lecture 125Modules on Stability Study : Stability Study - Fundamental Understanding | Interchangebility | Reports | API & FPP Stability Study
Lecture 126Climate Zone
Lecture 127Stability Zone Finder
Lecture 128Stability Studies : Case discussions
Lecture 129Case Study: Managing Stability Study for Zone IV countries
Lecture 130Accelerated and intermediate testing conditions
Lecture 131Long Term Stability Testing Requirements
Lecture 132Stability Study Protocol Development - Dosage form: Capsule
Lecture 133Stability Data Sheet
Lecture 134Dossier Stability Test
Lecture 135Testing Frequency
Lecture 136Bracketing
Lecture 137Matrixing
Section 10Biopharmaceutical Regulatory Affairs (Innovative Biologics and Biosimilars / Similar Biologics)
Lecture 138Introduction to Biopharmaceuticals | Biopharma Market | Overview 
Lecture 139Classification of Biopharmaceutical 
Lecture 140Chemical Drugs Vs. Biologic Drugs
Lecture 141Principle of Naming of Biologic | Understanding on MAB naming system 
Lecture 142Recombinant protein
Lecture 143Monoclonal Antibodies Vs. Polyclonal Antibodies
Lecture 144Monoclonal Antibodies
Lecture 145Synthetic Immunomodulators
Lecture 146Production of Monoclonal Antibodies
Lecture 147Cytokines
Lecture 148Interferon
Lecture 149Erythropoiesis-stimulating agent
Lecture 150Biological Licensing Application (BLA) 
Lecture 151Abbreviated Biosimilar Application - 351(k): Advance Strategic Planning Process : Originator Vs. Biosimilar Development and Regulatory Approval Process | Reference Biologic | Purple Book | Data Requirements
Lecture 152Purple Book: Significance | Searching | Assignments
Lecture 153Vaccine development and approval Process
Lecture 154Biosimilar Development Process
Lecture 155Strategic Consideration for Biosimilar Development 
Lecture 156Bio-Manufacturing Process Information
Lecture 157Studies required for approval of biosimilar
Lecture 158Regulatory Requirements for Biosimilar | Stepwise evidence based development | Analytical Similarity | Clinical Study | PKPD study requirements | CMC expectation of Biosimilar
Lecture 159Comparability of Biologics | Different Categories of Comparability | General Principles 
Lecture 160CQA (Critical Quality Attribute) and CPP (Critical Process Parameter)
Lecture 161ATMPs | Types and Classification | Regulatory Mechanism 
Lecture 162CAR-T Therapy | Different Types of CAR-T Therapy | Mechanism of action | Challenges | Brainstorming on Concept of Personalized Medicine | Understanding on marketed formulation
Lecture 163Live Biotherapeutic Products | LBPs | Class | Mechanism | Indication Positioning | Regulatory Requirements for LBPs 
Section 11Pharmacovigilance and Drug Safety
Lecture 164Introduction to Pharmacovigilance
Lecture 165Introduction to Adverse Drug Reactions
Lecture 166ADR: Pharmacology
Lecture 167ADR controversies
Lecture 168ADR: Classification
Lecture 169PV and ADR Monitoring
Lecture 170ADR and Related Terminologies
Lecture 171ADR Reporting System 
Lecture 172DoTS
Lecture 1734 Elements of AEs
Lecture 174ADR Reporting Limitations
Lecture 175ADR Detection - Pre Marketing Vs. Post Marketing Trial
Lecture 176The Adverse Drug Reaction (ADR) Probability Scale
Section 12Pharmacovigilance Process
Lecture 177Pharmacovigilance Process
Lecture 178PSURs
Lecture 179Risk Management
Section 13Pharmacovigilance regulatory authorities
Lecture 180Introduction
Lecture 181United States - USFDA
Lecture 182COSTART
Lecture 183MedDRA
Lecture 184Pharmacovigilance Regulation in Emerging economies, including Latin America
Lecture 185European Union
Lecture 186The World Health Organization (WHO)
Lecture 187WHOART
Lecture 188The International Conference on Harmonization (ICH)
Lecture 189The Council for International Organizations of Medical Sciences (CIOMS)
Lecture 190The International Society of Pharmacovigilance (ISoP)
Lecture 191Active surveillance schemes
Lecture 192EudraLex
Section 14Pharmacovigilance Frame Work
Lecture 193Pharmacovigilance Framework
Lecture 194SmPC / SPC
Lecture 195Pharmacovigilance Software
Lecture 196Good Pharmacovigilance Process (GPVP)
Section 15Add on Learning
Lecture 197Case Study - Pharmacovigilance Frame Work Implementation
Lecture 198Role of Drug Safety Associates
Section 16AI in Pharmacovigilance and Drug Regulatory Affairs
Lecture 199Introduction to AI
Lecture 200Basics of AI ML DL | Key Differences | Application in industry
Lecture 201Types of AI
Lecture 202AI Project | Overview
Lecture 203Comprehensive Training on AI Project | Managing Stages | AI Iteration 
Lecture 204How machine learning
Lecture 205Understanding Regulatory Affairs – Traditional vs. Digital | 2 Case Study
Lecture 206Basics of AI for Regulatory Professionals | Understanding different models used in RA | Case Study | Simulation
Lecture 207AI Application across drug life cycle | Case Analysis | Model predictions
Lecture 208AI Terms with Regulatory Significance | Regulatory Applications
Lecture 209NLP in Regulatory Affairs | Conceptual understanding | Usage | NLP in Labeling
Lecture 210Data Grouping with Unsupervised Learning | Case Simulation | Hands on Exercise
Lecture 211Quality Data and Bias | Bias in datasets | Different Types of Bias in Pharma Datasets 
Lecture 212AI Data Quality Standard | Checklist
Lecture 213Download AI Data Quality Checklist
Lecture 214Case Study: Accelerated Approval Using Real-World Evidence AI
Lecture 215AI Model for Dossier Submission and Filing - Model Selection | Simulation
Lecture 216AI Technologies in RA
Lecture 217Structured Vs. Unstructured Data | Practical Understanding | Explore Patient Datasets
Lecture 218Sample Data Exercise | Data error | Data Refinement and Cleaning of the data 
Section 17AI in Regulatory Authoring and CMC Writing
Lecture 219AI-Powered Regulatory Document Authoring and CMC Writing
Lecture 220AI Tools Comparison - Authoring and CMC Writing (Module 2 & 3)
Lecture 221Tips for Selecting AI Tools (CMC Authoring)
Lecture 222CMC - AI Workflow Checklist | Simulation Based Cases
Lecture 223HITL Regulatory Document Authoring
Lecture 224Confidence Score in Regulatory Authoring | Case Simulation in CMC Authoring
Lecture 225Confidence Scores in Data Extract in Regulatory Writing [Case Simulation]
Section 18eCTD v4.0 Training
Lecture 226eCTDV4.0 Fundamental Understanding | Structures | Key Features
Lecture 227eCTDV4.0 Structure | Lifecycle Management 
Lecture 228eCTD Validation | Managing Validation | Tool Types | Types of Error | Validation Error Management
Lecture 229eCTD Validation Tools
Lecture 230eCTD Publishing Cycle
Lecture 231HL7 - Structure and Understanding in the context of eCTD V4.0
Lecture 232Tips and Submission Readiness Checklist
Lecture 233eCTD Submission Checklist Format
Section 19Risk and Compliance Management
Lecture 234AI and Data Integrity | Regulatory Documentation | Case Based Learning | Understanding Data Integrity Principles | Application and Use Cases
Lecture 235Cases of data breaches with explanation
Lecture 236Case Based Discussion : Data Breach in AI-Assisted CMC Drafting 
Section 20 Labelling and CCDS Management
Lecture 237CCDS Management 
Lecture 238CCDS Management Tools - Native, AI Plus | Key Functionalities
Lecture 239AI Augmented Labelling Compliance System
Lecture 240Label Drift in CCDS Management | Simulation Case Study | AI Based Workflow in Label Drift detection and management
Lecture 241AI Review of Labels, PI and SMPC with help of the Case Based Simulation | 4 Case Simulations 
Lecture 242CCDS Management Case Study | Pregnancy Warning Upgrade Case Study
Lecture 243CCDS Management Case Study | Dosage Section Conflict | Case Based Analysis
Lecture 244Centralized Artwork Operation | Mechanism | Operation Step Planning 
Lecture 245Case Study on Centralized Artwork Operation  [Recall Management]
Lecture 246Artwork Management Terms | Key Understanding on Terminologies | Usage in Artwork Cases
Section 21Real World Evidence and Real World Data | Strategic Decision Making
Lecture 247Evidence Based Decision Making | Combine evidences for decision making | Do we need more evidence? 
Lecture 248RWD and RWE | Potential sources of RWE | Traditional RCTs vs. RWE | Case Study - RWE Programs | Influencing HCP decision-making
Lecture 249RWD and RWE in Product Lifecycle Management
Lecture 250RWD and RWE - Fit to use | Assessment 
Lecture 251RWD data sources | Different types | Detailed understanding of each class 
Lecture 252RWD Study Design
Lecture 253RWE Published Tool | Insights on commonly used tools
Lecture 254Healthcare Reimbursement Models : Value Based Care | Fee for Service (FFS) Model | Other Reimbursement Models
Lecture 255Consensus Narrative Review 
Lecture 256Electronic Patient Data | EMR | EHR | Differences | Software architecture and characteristics
Lecture 257Active Surveillance Schemes | Active Case Finding |Sentinel Surveillance | Cohort Studies | Vaccine Safety Surveillance | Pharmacovigilance Programs | Disease Registries |Event Monitoring
Lecture 258RWD Characteristics
Lecture 259RCT vs. RWE Comparison | Case Based Analysis
Lecture 260RCT and RWE Comparison
Section 22Working on Healthcare Datasets
Lecture 261Introduction to Healthcare Datasets
Lecture 262Dataset 1: Claims Data (Insurance)
Lecture 263Dataset 2: Retail Pharmacy Prescription Data
Lecture 264Dataset 3: Longitudinal Patient Data
Lecture 265Characteristics of Different Set of Healthcare Data
Lecture 266Reimbursement and Pricing Datasets
Lecture 267RWE Data Sources & Quality Considerations Checklist | Case Based Analysis
Lecture 268Triangulation and benchmarking | Enhancing Data Validation Through Cross-Referencing
Lecture 269RWD & RWE Case Database
Lecture 270RWE Large Dataset for Data Crunching Exercises |Data cleaning & preprocessing | Comparative Effectiveness Analysis 
Section 23AI Tools, Ethics and Future Landscape
Lecture 271AI Reg Tools - Review | Understanding Capabilities
Lecture 272Regulatory Authority View on AI Adoption
Lecture 273Data Sensitivity | Levels | Consequences | Management
Lecture 274Governance Flowchart – AI Tools in GxP Environments
Section 24Governance Flowchart – AI Tools in GxP Environments
Lecture 275RA Example - Generalist Vs. Specialist AI Tools
Lecture 276AI Generalist Overview (Life Science Focus)
Lecture 277Horizontal vs Vertical AI Tools
Lecture 278AI Tool Assessment Test 
Lecture 279Citation Verification Workflow | AI Tools Management | Hallucination and HITL Action Plan 
Section 25Prompt Engineering
Lecture 280Prompt Engineering – Basic Foundations of Prompt Writing | Different Prompt Framework | Case Based Examples
Lecture 281Special Prompting Structure - Case Based Prompt Designing 
Lecture 282Special Prompting Structure - Case Based Prompt Designing 
Lecture 283Workflow for writing AI Prompts with Life Science Industry Use Cases
Lecture 284PE Parameters | Controlling Creativity, Accuracy, and Output Behavior for Life-Science Applications | Simulation based decision making
Lecture 285How to adjust the parameters | Techniques 
Lecture 286Creating A Detailed Regulatory Prompt | Designing Structured Prompt in Code Editor
Section 26Regulatory Authoring and Publishing
Lecture 287Introduction to Regulatory Publishing | eCTD | NeSS | Regulatory Submission Workflow | Key Competencies Required for Regulatory Publishing Professionals
Lecture 288Overview of Global Regulatory Agencies and how their expectations impact regulatory publishing and submission workflows
Lecture 289Types of Regulatory Documents | Implications from regulatory publishing point of view 
Lecture 290Regulatory vs Cross-Functional Documents | Document Ownership Mapping | Document Workflow: From Authoring to Submission
Lecture 291Core Characteristics of Regulatory Documents | Clarity and Readability | Formatting Compliance | Navigability (Bookmarks, Hyperlinks) | File-Naming Standards | Version Control & Document Finalization | Metadata | Lifecycle Operator | Granularity | OCR | Annotations, Comments & Markups
Lecture 292Characteristics of Module-Specific Documents | How Publishing Ensures Document Integrity | Common Document Errors & How Publishing Detects Them
Lecture 293Cross Functional Review Mechanism 
Lecture 294Best Practices CFD Review
Lecture 295Regulatory Publishing Collaboration Workflow
Lecture 296Regulatory Publishing Document Control Challenges
Lecture 297Document Control Checklist
Lecture 298Leaf Structure Analysis | Common Error in Leaf Structuring
Lecture 299Formatting Rules Templated and Agency Specification
Lecture 300Versioning for Regulatory Publishing
Lecture 301File Naming Standard
Lecture 302Text Recognition and Optical Character Recognition (OCR)
Lecture 303Versioning File Naming OCR - How they work together
Lecture 304Final Document Assembly
Lecture 305Visual Diagram : eCTD Structure and XML Hierarchy
Lecture 306TOC and CI Management
Lecture 307Initial Submission & Maintenance Submission
Lecture 308Managing Lifecycle Operators - NEW REPLACE DELETE APPEND
Lecture 309eCTD Dossier Lifecycle - Multi Sequence View
Lecture 31010 Year eCTD Lifecycle : Sequence Evolution Diagram
Lecture 311Global Decision Tree - Classifying Post Approval Changes
Lecture 312eCTD Technical Validation | Typical issues | Resolutions
Lecture 313eCTD Validation Readiness Checklist
Lecture 314QC Checklist Design and Pre Submission Review
Lecture 315Submission Gateway | FDA ESG • EMA CESP • Health Canada Portal • PMDA Gateway
Lecture 316Regulatory Publishing Simulation 
Lecture 317Pre-Gateway Submission Review Checklist | Post Submission Confirmation
Section 27Final Examination
Lecture 318Final Examination
Lecture 319Request for Course Certificate